R

    Rigel Pharmaceuticals Inc (RIGL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $46.18
    -0.30 (-0.65%)

    Market Cap: $868.24M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    75%(30/40)
    Avg Surprise
    +72.58%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.96
    Range$0.77 - $1.07
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate Drift
    90d ago$1.27+32.2%
    60d ago$1.27+32.2%
    30d ago$1.22+27.1%
    7d ago$0.89-8.0%
    Current$0.96
    Revenue Consensus
    $80M
    Range$75M - $83M
    5 analysts
    Dec 31, 2026
    EPS Consensus$1.78
    Range$0.79 - $2.85
    4 analysts
    Revenue Consensus
    $108M
    Range$96M - $121M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.78---
    Sep 26EST
    		-$0.96---
    Jun 26
    		$0.88$0.91-3.30%Miss-73.2%
    Mar 26
    		$0.44$0.87-49.43%Miss-30.2%
    Dec 25
    		$1.12$1.20-6.80%Miss+40.0%
    Sep 25
    		$1.46$0.94+55.32%Beat+108.6%
    Jun 25
    		$3.28$1.41+132.62%Beat+5566.7%
    Mar 25
    		$0.63$0.09+600.00%Beat+226.0%
    Dec 24
    		$0.80$0.58+38.19%Beat+18947.6%
    Sep 24
    		$0.70$0.06+1066.67%Beat+333.3%
    Jun 24
    		$-0.06N/A+66.67%Beat+85.0%
    Mar 24
    		$-0.50$-0.27-85.19%Miss+37.5%
    Dec 23
    		$0.00N/A+114.00%Beat-58.0%
    Sep 23
    		$-0.30N/A+54.55%Beat+72.7%
    Jun 23
    		$-0.40$-0.80+50.00%Beat+50.0%
    Mar 23
    		$-0.80$-0.93+13.98%Beat+50.0%
    Dec 22
    		$0.01N/A+109.09%Beat+107.7%
    Sep 22
    		$-1.10$-1.36+19.12%Beat+8.3%
    Jun 22
    		$-0.80$-1.21+33.88%Beat+0.0%
    Mar 22
    		$-1.60$-1.36-17.65%Miss-172.7%
    Dec 21
    		$-0.13$-0.13+0.00%Beat-18.2%
    Sep 21
    		$-1.20$-1.00-20.00%Miss-50.0%
    Jun 21
    		$-0.80$-1.15+30.43%Beat+20.0%
    Mar 21
    		$2.20$0.30+633.33%Beat+1592.3%
    Dec 20
    		$-0.11$-0.11+0.00%Beat+89.0%
    Sep 20
    		$-0.80$-1.22+34.43%Beat-14.3%
    Jun 20
    		$-1.00$-1.33+24.81%Beat+16.7%
    Mar 20
    		$0.13$0.13+0.00%Beat+111.8%
    Dec 19
    		$-1.00$-0.85-17.65%Miss-3433.3%
    Sep 19
    		$-0.70$-1.07+34.58%Beat+50.0%
    Jun 19
    		$-1.20$-1.37+12.41%Beat+25.0%
    Mar 19
    		$-1.10$-1.28+14.06%Beat+35.3%
    Dec 18
    		$0.03$0.03+0.00%Beat+116.7%
    Sep 18
    		$-1.40$-1.50+6.67%Beat+0.0%
    Jun 18
    		$-1.60$-1.62+1.23%Beat+0.0%
    Mar 18
    		$-1.70$-1.70+0.00%Beat-20.6%
    Dec 17
    		$-0.18$-0.13-38.46%Miss-12.5%
    Sep 17
    		$-1.40$-1.53+8.50%Beat+22.2%
    Jun 17
    		$-1.60$-1.50-6.67%Miss-
    Mar 17
    		$-1.41$-1.08-30.56%Miss-
    Dec 16
    		$-0.16$-0.17+5.88%Beat-
    Sep 16
    		$-1.80$-2.21+18.55%Beat-

    Key Metrics

    Valuation
    P/E Ratio11.84EV/EBITDA8.71x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin116.30%Operating Margin29.90%
    ROE126.90%ROIC18.73%
    Financial Health
    Debt/Equity0.09xInterest Coverage15.00x
    Current Ratio1.94xQuick Ratio1.79x
    Trading Statistics
    Beta1.17Avg Volume341.69K
    52-Week High$52.2452-Week Low$24.95

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$45.96
    SMA 20$43.48
    SMA 50$40.88
    SMA 200$36.24
    EMA 10$45.52
    EMA 20$43.93
    EMA 50$40.65
    EMA 200$35.20

    MACD

    Line: 2.03Signal: 1.86Hist: 0.17

    ADX

    ADX: 34.0+DI: 25.3-DI: 11.4

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down16.0
    PSAR$43.74

    Bollinger Bands

    Upper Band$49.08
    Lower Band$37.87
    %B Position2578%(Upper)
    Band Width0.74

    RSI (14-Day)

    Neutral
    63.3

    Momentum Oscillators

    Stoch %K86.8
    Stoch %D88.7
    Williams %R-17.9
    ROC (10d)8.8%
    Momentum3.73
    CCI (20d)73.2
    MFI (14d)51.4

    Volatility Measures

    ATR (14d)$1.89(4.1%)
    StdDev (20d)2.80
    Hist Vol46.7%(High)

    Volume Flow

    VWAP$46.03
    OBV-2.4M
    AD Line1.8M
    CMF (20d)0.091

    Volume Metrics

    Avg Vol (20d)349.4K
    Vol Ratio0.6x
    VWMA (20d)$43.27

    Pivot Points

    R3$48.06
    R2$47.43
    R1$46.95
    Pivot Point$46.32
    S1$45.84
    S2$45.21
    S3$44.73

    Advanced Oscillators

    TSI29.02
    Ultimate Osc62.7
    KST150.10

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$78.70M$58.82M$69.80M$69.46M$101.69M$53.33M$57.60M$55.31M$36.84M$29.53M$35.79M$28.13M
    Cost of Revenue$8.53M$4.61M$5.96M$4.75M$4.50M$4.41M$5.79M$8.03M$2.81M$2.02M$3.79M$1.27M
    Gross Profit$70.18M$54.21M$63.85M$64.71M$97.18M$48.92M$51.81M$47.28M$34.03M$27.51M$32.00M$26.87M
    Operating Expenses$46.60M$42.33M$40.68M$36.29M$36.08M$36.15M$35.15M$33.23M$33.59M$34.48M$30.04M$31.33M
    R&D$13.96M$11.68M$10.69M$7.35M$6.82M$8.44M$5.63M$6.18M$5.54M$6.03M$3.19M$6.47M
    SG&A$32.64M$30.65M$29.99M$28.94M$29.26M$27.71M$29.52M$27.04M$28.05M$28.45M$26.85M$24.86M
    Operating Income$23.57M$11.88M$23.17M$28.42M$61.10M$12.77M$16.66M$14.06M$447,000$-6,966,000$1.97M$-4,465,000
    Interest Income$789,000$1.21M$1.24M$1.09M$753,000$591,000$522,000$425,000$552,000$593,000$678,000$672,000
    Interest Expense$779,000$1.43M$1.70M$1.89M$1.87M$1.85M$1.96M$2.06M$2.03M$1.87M$1.91M$1.90M
    Income Before Tax$23.59M$11.66M$22.71M$27.62M$59.98M$11.51M$15.22M$12.42M$-1,030,000$-8,247,000$737,000$-5,692,000
    Income Tax Expense$6.29M$3.00M$-245,351,000$-280,000$369,000$65,000$881,000$0$0$0$0$0
    Net Income$17.29M$8.65M$268.06M$27.90M$59.61M$11.45M$14.34M$12.42M$-1,030,000$-8,247,000$737,000$-5,692,000
    EBITDA$24.39M$12.31M$23.53M$28.56M$61.46M$13.19M$16.98M$14.60M$901,000$-6,771,000$2.00M$-4,278,000
    EBIT$23.57M$11.88M$23.17M$28.42M$61.10M$12.77M$16.66M$14.06M$447,000$-6,966,000$1.97M$-4,465,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RIGL

    News

    Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Increased to Hold at Zacks Research

    Zacks Research upgraded Rigel Pharmaceuticals (NASDAQ:RIGL) from a "strong sell" to a "hold" rating, while other analysts maintained or raised their price targets. The company recently reported strong quarterly earnings, significantly beating analyst expectations for both EPS and revenue. Institutional investors hold a substantial stake in Rigel Pharmaceuticals.

    MarketBeat•8/19/26•
    Bullish

    HC Wainwright Analysts Increase Earnings Estimates for RIGL

    HC Wainwright analysts have increased their Q3 2026 earnings per share estimate for Rigel Pharmaceuticals (NASDAQ:RIGL) to $0.99 from $0.68, maintaining a "Buy" rating and an $85 price target. This revision follows Rigel's strong quarterly results, where EPS of $0.88 significantly beat the $0.09 consensus and revenue of $78.7 million surpassed expectations of $55.27 million. The firm also provided optimistic full-year earnings projections through 2030, while overall analyst sentiment remains mixed with an average "Hold" rating and a $59.00 consensus price target.

    MarketBeat•8/18/26•
    Bullish

    Piper Sandler Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $49

    Piper Sandler has reiterated its Hold rating on Rigel Pharmaceuticals (RIGL.US) and increased its price target to $49. This adjustment reflects the firm's continued evaluation of the company's financial and market position.

    Moomoo•8/17/26•
    Somewhat-Bullish

    Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope

    Rigel Pharmaceuticals (RIGL) has seen its fair value estimate increase from US$51.6 to US$61.2 per share, primarily due to the launch of Veppanu in the U.S. and the international potential of Rezlidhia through a partnership with Kissei. Analysts, such as H.C. Wainwright, view Veppanu as a new growth engine and have raised their price target for RIGL, although execution risk for both products remains a key factor for investors to monitor. The fair value adjustment also reflects changes in revenue growth assumptions, net profit margin expectations, and future P/E multiples.

    Yahoo Finance•8/16/26•
    Bullish

    (RIGL) Price Dynamics and Execution-Aware Positioning

    This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) focusing on its price dynamics and execution-aware positioning based on AI models. It identifies strong near and mid-term sentiment, compelling upside potential due to a lack of resistance levels above the current price, and outlines specific institutional trading strategies (Position, Momentum Breakout, and Risk Hedging). The analysis also provides multi-timeframe signal strengths and support/resistance levels for RIGL.

    Stock Traders Daily•8/15/26•
    Bullish

    Frequently Asked Questions About RIGL

    Does RIGL pay dividends?
    Rigel Pharmaceuticals Inc (RIGL) does not currently pay a regular dividend.
    What is RIGL's P/E ratio?
    Rigel Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 11.84.
    What is RIGL's market cap?
    Rigel Pharmaceuticals Inc (RIGL) has a market capitalization of $868.24M with a current stock price of $46.18.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In